Zhejiang Haichang Bio-Tech Co., Ltd.

Beijing’s Tsinghua University will invest $276M in a JV to build a new biohub in the UK’s Cambridge Science Park. February 10, 2018 Deals and Financings Beijing’s Tsinghua University will invest $276 million in a JV to build a new biohub in the UK’s Cambridge Science Park; Jing Medicine (Shanghai) formed a $100 million collaboration to develop small molecule cancer drugs with ShanghaiTech University; Beijing InnoCare Pharma raised $55 million in a funding round led by Vivo Capital to develop novel drugs for cancer and autoimmune diseases; China’s GeneScience was a new investor in Rani Therapeutics’ latest $53 million funding for its oral drug delivery of injectible drugs; Cellular Biomedicine, a China-US biopharma, raised $30.6 million from Sailing Capital to support a CAR-T immunotherapy; Luqa Pharma of Hong Kong closed a $15 million Series B financing round to develop a portfolio of in-licensed dermatology and aesthetic products for China; Roivant Sciences, a Swiss-US in-licensing company, will collaborate with ArQule to develop a cancer treatment in China; NetVation DL Medicine, a Chengdu subsidiary of HitGen, entered a two-year research collaboration to discover new drugs for Pfizer; Zhejiang Haichang Biotech will develop a new formulation of a Rexahn liver cancer treatment for China use; China Resources Pharma acquired China rights to a long-acting treatment for prostate cancer from Sweden’s Xbrane Biopharma; Trials and Approvals Hong Kong’s Golden Meditech was granted FDA GMP certification for its Houston T-Cell processing facility; Beijing’s BeiGene launched a Celgene cancer drug, Vidaza®, in China. Stock Symbols: (NSDQ: CBMG) (NSDQ: ARQL) (NYSE: PFE) (NYSE American: RNN) (HK: 3320) (HK: 00801) (NSDQ: BGNE) (NSDQ: CELG)